Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

pembrolizumab 1epacadostat 1copanlisib 1Nivolumab 1Fulvestrant 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Spinocerebellar Degenerations × copanlisib × Clear all
NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
48 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡